Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923223 | 1.00 | TNKS2 (0.39) | TNKS2PTPN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3224700 | 0.84 | PTPN1 (0.45) | PTPN1PTPN2 | |
| SCHEMBL3224724 | 0.84 | PTPN1 (0.45) | PTPN1PTPN2 | |
| SCHEMBL3920216 | 0.83 | TNKS2 (0.40) | TNKS2PTPN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1731124 | 0.81 | TNKS2 (0.43) | TNKS2PTPN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL4129304 | 0.81 | TNKS2 (0.35) | TNKS2ALDH1A1MAPTHSD17B10KDM4C | |
| SCHEMBL4129302 | 0.81 | TNKS2 (0.35) | TNKS2ALDH1A1MAPTHSD17B10KDM4C | |
| SCHEMBL3918065 | 0.79 | PTPN1 (0.46) | PTPN1ALDH1A1MAPTHSD17B10KDM4C | |
| SCHEMBL3921475 | 0.79 | PTPN1 (0.41) | TNKS2PTPN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3921485 | 0.79 | PTPN1 (0.41) | TNKS2PTPN1ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-1686990-A4 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-7101902-B2 | 2-guanidinylimidazolidinedione compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1686990-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005072082-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | GUCY1B2, GUCY1A2, AGK | TNKS2 1145/4885PTPN1 4265/4885ALDH1A1 677/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | TNKS2 1042/4885PTPN1 21/4885ALDH1A1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.